Predicting and preventing the future: actively managing multiple sclerosis
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI
- Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
- Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
- Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis
- Brain macro- and microscopic damage in patients with paediatric MS
- Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis
- Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up
- Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients